{"transactions":[{"id":2061557,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":120901,"kind":"person","name":"Lindmark Bertil","position":1,"cik":"0001825778","reported_name":"Lindmark Bertil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-05T21:00:25.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 4, 2024 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":115000,"derivative":{"exercise_price":1.21,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001209191-23-001755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919123001755/doc4.xml","form_type":"4"}},{"id":2319649,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":120901,"kind":"person","name":"Lindmark Bertil","position":1,"cik":"0001825778","reported_name":"Lindmark Bertil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-23T12:00:14.000Z","date":"2022-03-22","kind":"purchase","acquired":true,"shares":14604,"price":2.16,"value":31544.64,"ownership":{"direct":true},"balance_after":16604,"source":{"system":"sec-edgar","filing":"0001209191-22-020683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919122020683/doc4.xml","form_type":"4"}},{"id":2440959,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":120901,"kind":"person","name":"Lindmark Bertil","position":1,"cik":"0001825778","reported_name":"Lindmark Bertil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T22:00:36.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":118750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 4, 2023 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":118750,"derivative":{"exercise_price":3.24,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":118750},"source":{"system":"sec-edgar","filing":"0001209191-22-002214","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919122002214/doc4.xml","form_type":"4"}},{"id":2652975,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":120901,"kind":"person","name":"Lindmark Bertil","position":1,"cik":"0001825778","reported_name":"Lindmark Bertil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-28T20:00:17.000Z","date":"2021-06-28","kind":"purchase","acquired":true,"shares":2000,"price":5.26,"value":10520.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001209191-21-043464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919121043464/doc4.xml","form_type":"4"}},{"id":2913221,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":120901,"kind":"person","name":"Lindmark Bertil","position":1,"cik":"0001825778","reported_name":"Lindmark Bertil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-07T21:00:07.000Z","date":"2021-01-05","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vested and became exercisable on January 5, 2022 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":95000,"derivative":{"exercise_price":13,"expiration_date":"2031-01-05","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-21-002475","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800315/000120919121002475/doc4.xml","form_type":"4"}}]}